Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 2: BIBW 2992 in EGFR-mutated NSCLC
NCT00525148Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Objective Response Rate up to 93 months. Started Aug 2007; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00525148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525148.